Xenon Pharmaceuticals (NASDAQ:XENE) Receives "Buy" Rating from HC Wainwright

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $53.00 target price on the biopharmaceutical company's stock. HC Wainwright's target price suggests a potential upside of 79.24% from the stock's current price. HC Wainwright also issued estimates for Xenon Pharmaceuticals' Q2 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.48) EPS, Q2 2026 earnings at ($1.34) EPS, FY2026 earnings at ($5.38) EPS, FY2027 earnings at ($5.70) EPS, FY2028 earnings at ($5.11) EPS and FY2029 earnings at ($3.61) EPS.

A number of other research analysts have also weighed in on XENE. The Goldman Sachs Group decreased their target price on Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Deutsche Bank Aktiengesellschaft began coverage on Xenon Pharmaceuticals in a report on Tuesday, February 11th. They set a "buy" rating and a $67.00 target price on the stock. William Blair reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Monday, May 5th. StockNews.com lowered Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, May 2nd. Finally, Chardan Capital reissued a "buy" rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $54.82.

Xenon Pharmaceuticals Stock Performance

NASDAQ XENE traded down $0.17 during trading on Tuesday, hitting $29.57. The stock had a trading volume of 1,147,831 shares, compared to its average volume of 508,722. The company has a market capitalization of $2.26 billion, a PE ratio of -10.49 and a beta of 1.21. The company's 50-day moving average price is $34.19 and its two-hundred day moving average price is $38.03. Xenon Pharmaceuticals has a 12 month low of $26.74 and a 12 month high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.07. The company had revenue of $7.50 million for the quarter, compared to analyst estimates of $1.64 million. During the same period last year, the firm earned ($0.62) EPS. As a group, equities analysts anticipate that Xenon Pharmaceuticals will post -3.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several hedge funds have recently made changes to their positions in XENE. Caitong International Asset Management Co. Ltd purchased a new position in Xenon Pharmaceuticals during the first quarter worth about $30,000. GF Fund Management CO. LTD. purchased a new position in Xenon Pharmaceuticals during the fourth quarter worth about $63,000. Quarry LP purchased a new position in Xenon Pharmaceuticals during the fourth quarter worth about $78,000. Blue Trust Inc. grew its position in Xenon Pharmaceuticals by 140.3% during the fourth quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company's stock worth $95,000 after buying an additional 1,414 shares in the last quarter. Finally, Avior Wealth Management LLC purchased a new position in shares of Xenon Pharmaceuticals in the 4th quarter worth about $101,000. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.